Gelonghui, January 21丨Brother Technology (002562.SZ) announced that Jiangxi Brother Pharmaceutical Co., Ltd. (“Brother Pharmaceuticals”), a wholly-owned subsidiary of the company, recently received the European Pharmacopoeia applicability certificate (“CEP certificate”) issued by the European Drug Quality Administration. Iohexol is widely used in angiography, subarachnography, coronary angiography, spinal cord and hip joints, urinary system imaging, CT enhanced scanning, etc., and has the advantages of low osmolarity, low neurotoxicity, low contrast density, and good tolerability. Currently, the global market demand for iohexol APIs is estimated to be about 5,000 tons. Major global manufacturers with large-scale iohexol API supply capacity include GE and Stari.